|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NMT1 |
Gene summary for NMT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NMT1 | Gene ID | 4836 |
| Gene name | N-myristoyltransferase 1 | |
| Gene Alias | NMT | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | P30419 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4836 | NMT1 | LZE2T | Human | Esophagus | ESCC | 2.46e-03 | 3.67e-01 | 0.082 |
| 4836 | NMT1 | LZE4T | Human | Esophagus | ESCC | 2.79e-04 | 1.88e-01 | 0.0811 |
| 4836 | NMT1 | LZE7T | Human | Esophagus | ESCC | 5.87e-06 | 3.14e-01 | 0.0667 |
| 4836 | NMT1 | LZE21D1 | Human | Esophagus | HGIN | 1.03e-02 | 1.49e-01 | 0.0632 |
| 4836 | NMT1 | LZE22D1 | Human | Esophagus | HGIN | 1.06e-03 | 1.61e-01 | 0.0595 |
| 4836 | NMT1 | LZE22T | Human | Esophagus | ESCC | 2.58e-04 | 2.67e-01 | 0.068 |
| 4836 | NMT1 | LZE24T | Human | Esophagus | ESCC | 5.95e-08 | 2.97e-01 | 0.0596 |
| 4836 | NMT1 | P1T-E | Human | Esophagus | ESCC | 3.04e-07 | 4.23e-01 | 0.0875 |
| 4836 | NMT1 | P2T-E | Human | Esophagus | ESCC | 7.90e-17 | 2.84e-01 | 0.1177 |
| 4836 | NMT1 | P4T-E | Human | Esophagus | ESCC | 2.27e-16 | 3.60e-01 | 0.1323 |
| 4836 | NMT1 | P5T-E | Human | Esophagus | ESCC | 6.14e-37 | 5.92e-01 | 0.1327 |
| 4836 | NMT1 | P8T-E | Human | Esophagus | ESCC | 1.88e-27 | 4.74e-01 | 0.0889 |
| 4836 | NMT1 | P9T-E | Human | Esophagus | ESCC | 1.26e-10 | 2.82e-01 | 0.1131 |
| 4836 | NMT1 | P10T-E | Human | Esophagus | ESCC | 1.05e-27 | 1.41e-01 | 0.116 |
| 4836 | NMT1 | P11T-E | Human | Esophagus | ESCC | 3.51e-18 | 6.10e-01 | 0.1426 |
| 4836 | NMT1 | P12T-E | Human | Esophagus | ESCC | 8.83e-20 | 3.37e-01 | 0.1122 |
| 4836 | NMT1 | P15T-E | Human | Esophagus | ESCC | 1.32e-16 | 4.56e-01 | 0.1149 |
| 4836 | NMT1 | P16T-E | Human | Esophagus | ESCC | 8.04e-22 | 2.03e-01 | 0.1153 |
| 4836 | NMT1 | P17T-E | Human | Esophagus | ESCC | 6.69e-16 | 5.44e-01 | 0.1278 |
| 4836 | NMT1 | P19T-E | Human | Esophagus | ESCC | 7.33e-05 | 6.20e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00486604 | Endometrium | AEH | regulation of smooth muscle cell proliferation | 43/2100 | 180/18723 | 1.09e-06 | 3.68e-05 | 43 |
| GO:200125210 | Endometrium | AEH | positive regulation of chromosome organization | 25/2100 | 82/18723 | 1.95e-06 | 5.93e-05 | 25 |
| GO:00486594 | Endometrium | AEH | smooth muscle cell proliferation | 43/2100 | 184/18723 | 2.04e-06 | 6.14e-05 | 43 |
| GO:00330022 | Endometrium | AEH | muscle cell proliferation | 51/2100 | 248/18723 | 1.26e-05 | 2.77e-04 | 51 |
| GO:00072657 | Endometrium | AEH | Ras protein signal transduction | 63/2100 | 337/18723 | 3.09e-05 | 5.66e-04 | 63 |
| GO:00426925 | Endometrium | AEH | muscle cell differentiation | 68/2100 | 384/18723 | 8.88e-05 | 1.30e-03 | 68 |
| GO:00330446 | Endometrium | AEH | regulation of chromosome organization | 36/2100 | 187/18723 | 8.27e-04 | 7.73e-03 | 36 |
| GO:00011017 | Endometrium | AEH | response to acid chemical | 28/2100 | 135/18723 | 9.24e-04 | 8.43e-03 | 28 |
| GO:00486613 | Endometrium | AEH | positive regulation of smooth muscle cell proliferation | 23/2100 | 104/18723 | 1.03e-03 | 9.15e-03 | 23 |
| GO:00432005 | Endometrium | AEH | response to amino acid | 24/2100 | 116/18723 | 2.14e-03 | 1.65e-02 | 24 |
| GO:00063258 | Endometrium | AEH | chromatin organization | 64/2100 | 409/18723 | 3.69e-03 | 2.52e-02 | 64 |
| GO:00712302 | Endometrium | AEH | cellular response to amino acid stimulus | 16/2100 | 71/18723 | 4.68e-03 | 2.99e-02 | 16 |
| GO:1904705 | Endometrium | AEH | regulation of vascular associated smooth muscle cell proliferation | 19/2100 | 90/18723 | 4.69e-03 | 2.99e-02 | 19 |
| GO:1990874 | Endometrium | AEH | vascular associated smooth muscle cell proliferation | 19/2100 | 91/18723 | 5.32e-03 | 3.32e-02 | 19 |
| GO:1904707 | Endometrium | AEH | positive regulation of vascular associated smooth muscle cell proliferation | 12/2100 | 49/18723 | 6.75e-03 | 3.94e-02 | 12 |
| GO:00712293 | Endometrium | AEH | cellular response to acid chemical | 17/2100 | 80/18723 | 6.76e-03 | 3.94e-02 | 17 |
| GO:0031453 | Endometrium | AEH | positive regulation of heterochromatin assembly | 5/2100 | 12/18723 | 7.10e-03 | 4.09e-02 | 5 |
| GO:0120263 | Endometrium | AEH | positive regulation of heterochromatin organization | 5/2100 | 12/18723 | 7.10e-03 | 4.09e-02 | 5 |
| GO:0051148 | Endometrium | AEH | negative regulation of muscle cell differentiation | 15/2100 | 68/18723 | 7.45e-03 | 4.23e-02 | 15 |
| GO:200125213 | Endometrium | EEC | positive regulation of chromosome organization | 26/2168 | 82/18723 | 9.70e-07 | 3.31e-05 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NMT1 | SNV | Missense_Mutation | c.344N>A | p.Arg115Gln | p.R115Q | P30419 | protein_coding | tolerated(0.08) | benign(0.138) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NMT1 | SNV | Missense_Mutation | novel | c.763N>T | p.Arg255Cys | p.R255C | P30419 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NMT1 | SNV | Missense_Mutation | novel | c.177N>T | p.Lys59Asn | p.K59N | P30419 | protein_coding | tolerated(0.12) | benign(0.264) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NMT1 | SNV | Missense_Mutation | c.732N>T | p.Glu244Asp | p.E244D | P30419 | protein_coding | deleterious(0.02) | benign(0.232) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NMT1 | insertion | Frame_Shift_Ins | novel | c.965_966insAGGTATTCATTGTCTGGTGACTTTATATAAGAAAGGAA | p.Thr323GlyfsTer15 | p.T323Gfs*15 | P30419 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| NMT1 | insertion | Frame_Shift_Ins | novel | c.792_793insAGTT | p.Arg265SerfsTer45 | p.R265Sfs*45 | P30419 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NMT1 | insertion | Frame_Shift_Ins | novel | c.793_794insCTACCATGCCAGGGGGCAGAAGGATTTGT | p.Arg265ProfsTer47 | p.R265Pfs*47 | P30419 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NMT1 | SNV | Missense_Mutation | novel | c.532G>C | p.Glu178Gln | p.E178Q | P30419 | protein_coding | tolerated(0.1) | probably_damaging(0.996) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| NMT1 | SNV | Missense_Mutation | novel | c.1368N>T | p.Met456Ile | p.M456I | P30419 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NMT1 | SNV | Missense_Mutation | c.10G>A | p.Glu4Lys | p.E4K | P30419 | protein_coding | deleterious_low_confidence(0.04) | benign(0.017) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |